

ovarian carcinomas, and has the potential of being used as a tumor marker and a novel target for the development of new treatments.

The technology relates to the finding that some non-small cell lung cancers (NSCLC) express the antigen mesothelin. Targeting the tumors with antibodies or immunotoxins that specifically bind mesothelin can be a potential new treatment for non-small cell lung cancer. The SSIP immunotoxin and its variants that specifically bind to mesothelin can be used for the treatment of NSCLC.

**Applications and Modality:** NSCLC can be treated by targeting mesothelin.

**Advantage:** Anti-mesothelin antibodies and immunotoxins are already available and being tested for several cancers.

**Development Status:** The technology is in pre-clinical stage of development.

**Inventors:** Ira H. Pastan (NCI) et al.

**Patent Status:** U.S. Provisional Application No. 60/891,923 filed 27 Feb 2007 (HHS Reference No. E-120-2007/0-US-01), entitled "Treatment of Non-Small Cell Lung Cancer with Mesothelin-Targeted Immunotoxins."

**Licensing Status:** Available for exclusive and non-exclusive licensing.

**Licensing Contact:** Jesse S. Kindra, J.D.; 301-435-5559; [kindraj@mail.nih.gov](mailto:kindraj@mail.nih.gov)

**Collaborative Research Opportunity:** The National Cancer Institute's Laboratory of Molecular Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize anti-mesothelin antibodies and immunotoxins. Please contact John D. Hewes, Ph.D. at 301-435-3121 or [hewesj@mail.nih.gov](mailto:hewesj@mail.nih.gov) for more information.

### **A Gene Expression Profile That Predicts Ovarian Cancer Patient Response to Chemotherapy**

**Description of Technology:** Ovarian cancer is a poor prognosis disease that remains the most lethal of all gynecologic malignancies. Warning symptoms do not occur until the tumor has already spread beyond the ovary, resulting in diagnosis at an advanced stage. As a result, there is a poor patient prognosis with only fifteen percent of women possessing advanced stage disease surviving for five years. Despite an initial clinical response of 80% to surgery and chemotherapy, most patients experience tumor recurrence within two years of treatment. The overwhelming majority of these patients will eventually develop chemoresistant disease and die.

Available for licensing are two gene signatures. One gene signature can predict whether a patient will initially respond to standard platinum-paclitaxel chemotherapy, but will relapse within six months of completing treatment. A second gene signature identifies patients who will show no response to therapy. This methodology may enable clinicians to identify patients who may be candidates for additional and/or novel chemotherapy drugs, and effectively choose appropriate cancer treatment. A unique feature of this signature is its derivation from pure, microdissected isolates of ovarian tumor cells, rather than undissected tissue. By utilizing this approach, the resulting gene list is specific to the cell type that causes the disease.

**Applications:** Method to detect if an ovarian cancer patient is sensitive to treatment with chemotherapeutic agents; Method to evaluate ovarian cancer patient chemoresponsiveness; Diagnostic tool to aid clinicians in determining appropriate cancer treatment; Methods to treat ovarian cancer identified by chemoresistant biomarkers compositions.

**Market:** Ovarian cancer is the fourth most common form of cancer in the U.S.; Ovarian cancer is three times more lethal than breast cancer; 15,310 deaths in the U.S. in 2006.

**Development Status:** The technology is currently in the pre-clinical stage of development.

**Inventors:** Michael J. Birrer (NCI) et al.

**Publication:** SC Mok et al. Biomarker discovery in epithelial ovarian cancer by genomic approaches. *Adv Cancer Res.* 2007;96:1-22.

**Patent Status:** U.S. Provisional Application No. 60/899,942 filed 06 Feb. 2007 (HHS Reference No. E-060-2007/0-US-01).

**Licensing Status:** Available for exclusive or non-exclusive licensing.

**Licensing Contact:** Jennifer Wong; 301/435-4633; [wongje@mail.nih.gov](mailto:wongje@mail.nih.gov).

### **Potent, Easy to Use Targeted Toxins as Anti-Tumor Agents**

**Description of Technology:** The invention discloses synthesis and use of novel derivatives of 2-[2'-(2-aminoethyl)-2-methyl-ethyl]-1,2-dihydro-6-methoxy-3H-dibenz-[de,h]isoquinoline-1,3-dione as targeted anti-tumor agents. The use of targeted toxin conjugates with anti-cancer antibodies, such as herceptin, is increasing. Based on a comparison with the structurally complex toxins, such as DM1, available in the market, these novel toxins are more stable in circulation, thus making the toxin-conjugates more tumor-selective and

less toxic. As such, these compounds are superior alternatives to the existing toxins.

The invention describes a potent and easy to synthesize toxin that can be used for generating a variety of prodrugs. These compounds can be attached to a ligand that recognizes a receptor on cancer cells, or to a peptide that is cleaved by tumor-specific proteases. The compounds are topoisomerase inhibitors and are mechanistically different from DM1 that targets tubulin.

The structure of the toxin allows it to be modified with a peptide linker that is stable, but rapidly cleaved in lysosomes after the compound is specifically taken up by cancer cells.

**Applications:** The compounds can be used for preparation of a variety of potent anti-cancer agents with low systemic toxicity.

**Advantages:** Easy to prepare; Structural features make these compounds more stable in circulation; Toxin conjugates are more tumor-selective and less toxic.

**Benefits:** 600,000 cancer deaths occurred in 2006 in spite of advances in cancer therapeutics. A major limitation of current therapeutics is their toxic side effects. This technology can effectively treat cancer with low systemic toxicity and thus improve overall survival and quality of life of patients suffering from cancer. The current cancer chemotherapeutic market is valued at \$42 billion and expected to grow.

**Inventors:** Nadya I. Tarasova, Marcin D. Dyba, Christopher J. Michejda (NCI).

**Development Status:** *In vitro* studies are completed and *in vivo* animal model studies are ongoing.

**Patent Status:** U.S. Provisional Application No. 60/844,027 filed 12 Sep. 2006 (HHS Reference No. E-160-2006/0-US-01).

**Licensing Contact:** Mojdeh Bahar, J.D.; 301/435-2950; [baharm@mail.nih.gov](mailto:baharm@mail.nih.gov).

Dated: June 19, 2007.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. E7-12337 Filed 6-25-07; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

### **National Heart, Lung, and Blood Institute; Amended Notice of Meeting**

Notice is hereby given of a change in the meeting of the National Heart, Lung, and Blood Institute Special Emphasis

Panel, July 18, 2007, 8 a.m. to July 18, 2007, 6 p.m., Hilton Crystal City, 2399 Jefferson Davis Hwy., Arlington, VA 22202 which was published in the **Federal Register** on June 15, 2007, FR 07-2972.

The meeting location was changed from Hilton Crystal City to State Plaza Hotel, Washington, DC. The rest of the information remains the same. The meeting is closed to the public.

Dated: June 20, 2007.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 07-3118 Filed 6-25-07; 8:45 am]

**BILLING CODE 4140-01-M**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Heart, Lung, and Blood Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel, Institutional National Research Service Award (T32s).

*Date:* July 10, 2007.

*Time:* 2 p.m. to adjournment.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Roy L. White, PhD, Review Branch/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7176, Bethesda, MD 20892-7924, 301-435-0310, [whiterl@nhlbi.nih.gov](mailto:whiterl@nhlbi.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: June 20, 2007.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 07-3121 Filed 6-25-07; 8:45 am]

**BILLING CODE 4140-01-M**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

#### **National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel, Fellowships SEP HH-92.

*Date:* July 31, 2007.

*Time:* 8:30 a.m. to 3 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Doubletree, Bethesda, MD.

*Contact Person:* Lorraine Gunzerath, PhD, MBA, Scientific Review Administrator, National Institute on Alcohol Abuse and Alcoholism, Office of Extramural Activities, Extramural Project Review Branch, 5635 Fishers Lane, Room 3043, Bethesda, MD 20892-9304, 301-443-2369, [lgunzera@mail.nih.gov](mailto:lgunzera@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants, National Institutes of Health, HHS)

Dated: June 19, 2007.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 07-3122 Filed 6-25-07; 8:45 am]

**BILLING CODE 4140-01-M**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute of General Medical Sciences; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Minority Programs Review Committee, MBRS Review Subcommittee B.

*Date:* July 16-17, 2007.

*Time:* 8:30 a.m. to 4 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Rebecca H. Johnson, PhD, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, Natcher Building, Room 3AN18C, Bethesda, MD 20892, 301-594-2771, [Johnsonrh@nigms.nih.gov](mailto:Johnsonrh@nigms.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS)

Dated: June 19, 2007.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 07-3123 Filed 6-25-07; 8:45 am]

**BILLING CODE 4140-01-M**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Commission Act, as amended (5 U.S.C. Appendix 2), notice